肺癌的放射性核素分子靶向治疗

Radionuclide molecular target therapy for lung cancer

  • 摘要: 肺癌严重危害民众的生命和健康,目前国内外肺癌的发病率和病死率还在不断上升。在城市中,肺癌的病死率占男性恶性肿瘤患者病死率的38 %,占女性恶性肿瘤患者病死率的16%,均居首位。尤其是非小细胞肺癌的治疗效果多年来一直没有显著提高。近年来,随着医学分子生物学技术和理论的发展以及对肺癌发病机制认识的不断深入,转染钠/碘转运体基因及分子靶向药物介导的肺癌放射性核素治疗成为治疗晚期肺癌新的研究方向。

     

    Abstract: Lung cancer harms people's health or even lives severely. Currently, the morbidity and mortality of lung cancer are ascending all over the world. Accounting for 38.08%of malignant tumor caused death in male and 16% in female in cities, ranking top in both sex. Especially, the therapy of non-small cell lung cancer has not been obviously improved for many years. Recently, sodium/iodide transporter gene transfection and the therapy of molecular target drugs mediated radionuclide are being taken into account and become the new research directions in treatment of advanced lung cancer patients with the development of technology and theory for medical molecular biology and the new knowledge of lung cancer's pathogenesis.

     

/

返回文章
返回